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Abstract
Chemotherapeutic agents are used in the treatment of many cancers, yet variable resistance and toxicities among
individuals limit successful outcomes. Several studies have indicated outcome differences associated with ancestry among
patients with various cancer types. Using both traditional SNP-based and newly developed gene-based genome-wide
approaches, we investigated the genetics of chemotherapeutic susceptibility in lymphoblastoid cell lines derived from 83
African Americans, a population for which there is a disparity in the number of genome-wide studies performed. To account
for population structure in this admixed population, we incorporated local ancestry information into our association model.
We tested over 2 million SNPs and identified 325, 176, 240, and 190 SNPs that were suggestively associated with cytarabine-,
59-deoxyfluorouridine (59-DFUR)-, carboplatin-, and cisplatin-induced cytotoxicity, respectively (p#10
24). Importantly, some
of these variants are found only in populations of African descent. We also show that cisplatin-susceptibility SNPs are
enriched for carboplatin-susceptibility SNPs. Using a gene-based genome-wide association approach, we identified 26, 11,
20, and 41 suggestive candidate genes for association with cytarabine-, 59-DFUR-, carboplatin-, and cisplatin-induced
cytotoxicity, respectively (p#10
23). Fourteen of these genes showed evidence of association with their respective
chemotherapeutic phenotypes in the Yoruba from Ibadan, Nigeria (p,0.05), including TP53I11, COPS5 and GAS8, which are
known to be involved in tumorigenesis. Although our results require further study, we have identified variants and genes
associated with chemotherapeutic susceptibility in African Americans by using an approach that incorporates local ancestry
information.
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Introduction
Genome-wide association (GWA) studies have been successful in
identifying common genetic variants associated with many diseases
and traits [1]. Nearly 90% of these studies have been completed in
populations of European ancestry [2]. Technical reasons for the
paucity of GWA studies in African populations include increased
population structure, which reduces effective sample size, and
reduced linkage disequilibrium (LD), which means genotyped SNPs
do not tag as many loci as in populations with larger LD-blocks [3].
Studies in populations of recent African ancestry are crucial because
additional variants present at higher frequencies in African
populations may be absent or rare in European populations. It is
unclear whether associations found in European populations can be
consistently replicated in African populations: decreased linkage
disequilibrium (LD) and gene by environment interactions could
contribute to lack of replication [4]. Importantly, the inclusion of
populations of diverse ancestry in genomic studies advances the goal
of reducing health disparities [3]. We chose to address these issues
byinvestigatingthegeneticsofchemotherapeuticsusceptibilityinan
African American population using both SNP- and gene-based
genome-wide approaches.
Previous studies have shown that individual response to
chemotherapy is partially due to genetic factors with heritability
estimates ranging from 0.3–0.4 [5]. Performing GWA studies for
chemotherapeutic response in a clinical setting is challenging due
to a number of confounders such as diet and concomitant
medications. Even more challenging is to obtain a large clinical
study population of African Americans treated with the same
dosage regimen that have been systematically evaluated for
response and toxicity. To overcome these challenges, we have
developed a cell-based model that employs Epstein Barr virus
(EBV)-transformed lymphoblastoid cell lines (LCLs) from different
world populations as useful discovery tools in genetic studies of
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e21920chemotherapeutic susceptibility [6–10]. Others have claimed non-
genetic factors such as baseline growth rate, EBV copy numbers
and ATP levels may influence drug-induced phenotypes in LCLs
[11]. We have shown that growth rate does associate with
chemotherapeutic-induced cytotoxicity and should be considered
in all LCL analyses, but baseline EBV copy numbers and ATP
levels do not associate with chemotherapeutic-induced cytotoxicity
[12]. Some SNPs associated with chemotherapeutic susceptibility
in LCL discovery studies have recently been successfully replicated
in patient populations by associating with phenotypes like tumor
response and overall survival, which demonstrates the utility of this
model [13,14]. In this study, we expand our model to cell lines
derived from African Americans.
We chose to focus on four distinct chemotherapeutic drugs,
cytarabine, capecitabine, carboplatin and cisplatin, because of
their use and importance in the treatment of African Americans.
Cytarabine is an antimetabolite and the mainstay of treatment for
acute myeloid leukemia (AML) [6]. In some AML patients,
resistance to cytarabine is a major reason for treatment failure and
in others, cytarabine is associated with several adverse side effects,
including myelosuppression and neurotoxicity [15–19]. In a study
by the Children’s Oncology Group of pediatric patients with
AML, patients with African ancestry had significantly worse
survival compared with patients of exclusively European ancestry
[20]. Capecitabine, an antimetabolite pro-drug commonly used to
treat breast and colon cancers, is associated with two well-
described toxicities: diarrhea and hand-foot syndrome, which
often result in treatment delays or dose-reductions [21,22].
Capecitabine is often used to treat triple negative breast cancer,
which disproportionately affects individuals of African ancestry
[23]. Capecitabine is also used to treat advanced stage colon
cancer and outcomes are worse for African Americans than
Caucasians [24]. Carboplatin and cisplatin are platinating
chemotherapy agents commonly used to treat lung, testicular,
head and neck, colorectal and gynecological cancers [25–29]. Both
agents are associated with particular toxicities, predominantly
myelosuppression for carboplatin and nephrotoxicity and ototox-
icity for cisplatin [30–32]. There is a higher mortality rate reported
for lung and gynecological cancers in African Americans
compared with Caucasians [33], both of which are commonly
treated with platinating agents [7]. Many of these outcome
disparities are likely influenced by socioeconomic factors, but
genetic variation is also thought to contribute [2,3].
LCLs from the International HapMap Project’s [34] African
American population from the Southwestern United States (ASW)
were used to perform genome-wide SNP- and gene-based
association studies for susceptibility to cytarabine, carboplatin,
cisplatin and 59-DFUR (LCLs do not express cytidine deaminase,
therefore we used 59-DFUR, which is produced from capecitabine
by the action of this enzyme). To account for population structure
in this admixed population, we incorporated local ancestry
information into our association model. Our local ancestry
approach differs from the traditional global ancestry approach
because it considers ancestry at each particular chromosomal
locus. Thus, in addition to identifying potential variants and genes
involved in chemotherapeutic drug response in African Ameri-
cans, our study contributes to understanding the complex trait
genetics of other phenotypes in any admixed population. We
identified SNPs associated with each of the four drug phenotypes
and an enrichment of carboplatin-associated SNPs in the top
cisplatin-associated SNPs. Using a recently developed gene-based
GWA approach [35], we identified 98 suggestive candidate genes
for chemotherapeutic susceptibility in the ASW LCLs (p#10
23).
This set included 14 genes that showed evidence of replication in
the Yoruba population from Ibadan, Nigeria (YRI, p,0.05). We
also show that many of the associated SNPs identified in the ASW
are not polymorphic in populations of European ancestry, which
highlights the need for genetic studies in diverse populations.
Results
Cytotoxicity phenotypes
Lymphoblastoid cell lines (LCLs) from 83 ASW individuals were
evaluated for cellular susceptibility to four chemotherapeutic drugs
(cytarabine, 59-DFUR, carboplatin and cisplatin) using a short-term
cell growth inhibition assay. For carboplatin and cisplatin, the percent
survival data were used to calculate the concentration at which 50%
growth inhibition occurred (IC50) for each cell line. The mean (6SD)
IC50 was 20.1 (67.1 mM) for carboplatin and 4.6 (64.0 mM) for
cisplatin. However, in evaluating cellular sensitivity to cytarabine and
59-DFUR treatment, some resistant cell lines did not result in 50% cell
growth inhibition, therefore the area under the survival-concentration
curve (AUC) was calculated for each cell line. The mean (6SD) AUC
was 1791 (6335 [%NmM]) for cytarabine and 2619 (6353 [%NmM])
for 59-DFUR. For drugs with both measurements, AUC is highly
correlated with IC50 (Spearman’s rho=0.98 for cisplatin and
rho=0.97 for carboplatin). Therefore, GWA results using different
phenotypes (either IC50 or AUC) can be compared.
Global ancestry vs. local ancestry in African Americans
The ASW is a recently admixed population containing some
chromosomal segments of African ancestry and some chromosomal
segments of European ancestry. On average, African American
genetic ancestry is 80% African and 20% European, but a wide
range of percentages have been observed [36]. One approach to
correct for population structure in admixed populations is to
compute principal components (PCs) to model ancestry differences
and use the significant PCs as covariates in the analysis. We used the
EIGENSTRAT method to compute principal components by
comparing ASW genotypes to HapMap reference populations YRI,
CEU (Northern and Western European descent from Utah), and
CHB (Han Chinese from Beijing) [37]. While the three reference
populations cluster tightly when the first two principal components
are plotted, the ASW individuals are more variable, mainly along
the YRI-CEU axis (Figure 1A).
The EIGENSTRAT PC approach measures global ancestry across
the entire genome and does not measure the ancestry at a particular
chromosomal locus. To detect chromosomal segments of distinct
ancestry in admixed populations, we employed HAPMIX, a new
algorithm developed by Price et al. [38]. HAPMIX allowed us to
estimate the number of African and European chromosomes in each
ASW individual at each SNP locus, using phased YRI and CEU data
as the reference parental populations. The number and size of
European ancestry blocks varied among ASW individuals. Therefore,
individuals with similar PCs, like NA19701 and NA19704 (Figure 1A),
may have very different local ancestry patterns (Figure 1B). We defined
the local ancestry as the predicted number of European ancestry
chromosomes (0–2) at each SNP locus. To better correct for possible
population stratification effects, the local ancestry at a particular SNP
was used as a covariate in the association test for that SNP.
SNP associations with chemotherapeutic-induced
cytotoxicity
Using local ancestry covariates to account for possible
population structure, we performed GWA studies between over
2 million SNPs in the ASW population and each drug-induced
cytotoxicity phenotype. The phenotypes were adjusted for growth
rate and the residuals were rank-transformed to normal prior to
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p#10
24, 325 SNPs were associated with cytarabine AUC, 176
with 59-DFUR AUC, 240 with carboplatin IC50, and 190 with
cisplatin IC50 (Figure 2). We chose p#10
24 as suggestive because
previous work has shown that SNPs associated with chemother-
apeutic drug susceptibility at this p-value threshold and below are
enriched for expression quantitative trait loci (eQTLs), an
important functional class [39]. Table S1 lists all ASW drug-
induced cytotoxicity-associated SNPs with p#10
24.
Although we have not generated gene expression data in the
ASW, we determined if cytotoxicity-associated SNPs were eQTLs
in the YRI, the most closely related population for which we have
expression data (see cis- and trans-acting targets in Table S1).
Several top SNPs for each drug were previously reported to be
eQTLs in the YRI population [40]. Examples include rs1543175,
which is 42 kb upstream of non-protein coding RNA 295
(NCRNA00295), is associated with ASW 59-DFUR AUC
(Figure 3A, p=3.4610
27), and is a trans-acting eQTL for
IKAROS family zinc finger 1 (IKZF1) in YRI (Table S1,
p=2 610
25). An intergenic SNP, rs417245, is associated with
ASW 59-DFUR AUC (Figure 3B, p=9.6610
27) and is a trans-
acting eQTL for 5-oxoprolinase (OPLAH) and 1-acylglycerol-3-
phosphate O-acyltransferase 4 (AGPAT4) in YRI (Table S1,
p#10
24). An example within a gene is rs9828664, a SNP in the
first intron of calcium channel, voltage-dependent, alpha 2/delta
subunit 3 (CACNA2D3) that associated with ASW carboplatin IC50
(Figure 3C, p=2.5610
26) and the expression of two genes in YRI
(Table S1). One rs9828664 gene expression association is cis-acting
(filamin B, beta, FLNB,p=8 610
23) and one is trans-acting (family
with sequence similarity 91, member A1, FAM91A1,p=8 610
25).
Cisplatin-associated SNPs are enriched for carboplatin-
associated SNPs
To compare the top SNP associations for different drug
phenotypes, we examined the p-value distributions of the top
190 cisplatin IC50 SNPs (p#10
24) in the other three sets of GWA
results. That is, we pulled the p-values for these 190 SNPs from the
59-DFUR AUC, cytarabine AUC and carboplatin IC50 datasets
and compared the p-value distribution of this subset to the entire
p-value distribution (.2 million SNPs) for each drug (Figure 4).
The most dramatic shift was seen for carboplatin IC50: the overall
p-value mean was 0.50 whereas the cisplatin-associated SNP
subset p-value mean was 0.025 (p=2.2610
2191). Therefore,
cisplatin-associated SNPs are enriched for carboplatin-associated
SNPs and common mechanisms may influence the effect of both
related drugs. Less dramatic, but still significant, shifts were seen
for cytarabine (overall mean 0.50, cisplatin-associated SNP mean
0.27, p=4.5610
224) and 59-DFUR (overall mean 0.51, cisplatin-
associated SNP mean 0.30, p=4.4 6 10
224). Similar shifts were
observed when different thresholds (from 10
23 to 10
25) were used
to choose the top cisplatin-associated SNPs or when the top
carboplatin-associated SNPs were examined in the other three sets
of GWA results (data not shown). Cytarabine-associated SNPs
were not enriched for 59-DFUR-associated SNPs (p=0.99). The
correlations (Pearson’s R) of the four drug phenotypes are shown
in Table 1.
Gene associations with chemotherapeutic-induced
cytotoxicity
Traditional GWA studies are designed to find individual SNPs
with relatively large effects, especially in cohorts of relatively small
sample size such as the ASW. They are not designed to detect
multiple smaller effects working in concert. If a gene contains more
than one variant affecting phenotype, multiple SNPs within the
gene or gene region may show marginal levels of significance. The
versatile gene-based association study (VEGAS) software was
developed to detect these effects by combining the contribution of
all SNPs in a gene into a test-statistic and correcting for linkage
disequilibrium by using simulations from the multivariate normal
distribution [35]. In our implementation of VEGAS, the SNP set
for each gene included any SNPs within the gene as well as SNPs
50 kb upstream of the start position and 50 kb downstream of the
Figure 1. Global ancestry and local ancestry estimates. (A) The first two principal components (PCs), a measure of global ancestry, are plotted
from the results of the genotype comparison of unrelated individuals in the four populations using EIGENSTRAT [37]. Two ASW individuals (NA19701
and NA19704) have similar PCs. (B) Shown are the predicted numbers of European chromosome copies, a measure of local ancestry, from the HAPMIX
analysis [38] at each SNP locus for ASW individuals NA19701 and NA19704 at chromosome 1.
doi:10.1371/journal.pone.0021920.g001
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from the initial GWA studies were used in the test-statistic
calculation.
In total, 17,723 genes annotated in the VEGAS software were
tested for association with each of the four drug-induced
phenotypes. At the suggestive threshold of p#10
23, 26 genes
associated with cytarabine AUC, 11 genes with 59-DFUR AUC,
20 genes with carboplatin IC50, and 41 genes with cisplatin IC50
(Figure 5, Table S2). We attempted to replicate these findings by
testing each of these 98 genes for association with its respective
phenotype in the YRI using the same VEGAS method. Fourteen
genes associated with the same drug cytotoxicity phenotype in the
YRI (p,0.05) as in the ASW discovery (Table 2). Genes that
associated with cytarabine AUC included tumor protein p53
inducible protein 11 (TP53I11, ASW p=3.3610
24, YRI
p=1.3610
23), calcitonin receptor (CALCR, ASW p=3.3610
24,
YRI p=0.038), stathmin-like 4 (STMN4, ASW p=5.2610
24,
YRI p=0.046), and kynurenine 3-monooxygenase (KMO, ASW
p=5.4 610
24,Y R Ip = 0 . 0 1 8 ) .T h r e eg e n e sa s s o c i a t e dw i t hc a r b o -
platin IC50 in both populations: SNF1-like kinase (SNF1LK,A S W
p=4.4 610
24, YRI p=0.028), ADP-ribosylation factor guanine
nucleotide-exchange factor 1 (ARFGEF1,A S Wp=5 . 7 610
24,Y R I
p=0.030), and COP9 constitutive photomorphogenic homolog
subunit 5 (COPS5, ASW p=7.5610
24, YRI p=0.023). ARFGEF1
(ASW p=8.6610
25, YRI p=0.017) and COPS5 (ASW p=
1.8610
24, YRI p=0.020) also associated with cisplatin IC50,a s
did centrosome and spindle pole associated protein 1 (CSPP1,A S W
p=2.4 610
24, YRI p=0.017) and leucine rich repeat containing 67
(LRRC67,A S Wp = 3 . 1 610
24, YRI p=0.020). These four genes
cluster together on chromosome 8 and the SNPs within them are in
linkage disequilibrium (Figure 6). Three additional genes associated
with cisplatin IC50 in both populations: PR domain containing 7
(PRDM7,A S Wp=3 . 9 610
24, YRI p=0.033), growth arrest specific
8( GAS8, ASW p=4.6610
24, YRI p=0.041), and organic solute
transporter alpha (OSTalpha, ASW p=8.7610
24, YRI p=0.014).
Discussion
African American populations are underrepresented in genetic
studies, especially those performed on a genome-wide scale.
Several studies have indicated an ancestry difference in outcome
among patients with various cancer types [7,20,23,24,33]. We
investigated the genetics of chemotherapeutic susceptibility in 83
LCLs derived from the HapMap ASW population. Using local
ancestry covariates [38] to account for population structure in the
ASW, we tested over 2 million SNPs and identified 325 that were
associated with cytarabine AUC, 176 with 59-DFUR AUC, 240
with carboplatin IC50, and 190 with cisplatin IC50 (p#10
24).
Figure 2. Genome-wide association results for chemotherapeutic-induced cytotoxicity in the ASW. Each point represents a SNP. Blue
lines are at the suggestive significance threshold of p=10
24. Red lines are at the genome-wide significance threshold of p=5610
28.
doi:10.1371/journal.pone.0021920.g002
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PLoS ONE | www.plosone.org 4 July 2011 | Volume 6 | Issue 7 | e21920Figure 3. Genomic regions associated with chemotherapeutic-induced cytotoxicity in the ASW population. (A) rs1543175, which is
42 kb upstream of non-protein coding RNA 295 (NCRNA00295), associated with ASW 59-DFUR AUC (p=3.4610
27) and is a trans eQTL in YRI (Table
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suggestive candidate genes: 26 genes for cytarabine, 11 genes for
59-DFUR, 20 genes for carboplatin and 41 genes for cisplatin
susceptibility (p#10
23). Fourteen of these genes showed evidence
of replication in the YRI (p,0.05).
One important reason for studying populations of African
descent is that common alleles present in African populations may
be rare or absent in other populations. For example, the minor
allele of the highlighted SNP rs9828664, which has a frequency of
0.29 and associated with increased carboplatin sensitivity in ASW
(Figure 3C), is not present in the HapMap population of European
ancestry from Utah (CEU). Of the 919 unique SNPs suggestively
associated with one or more chemotherapeutic-induced pheno-
types in ASW (p#10
24), 237 (25.8%) of them have a minor allele
frequency less than 0.05 in the CEU. The minor allele frequency
in the CEU is zero for 116 (12.6%) of the ASW-associated SNPs.
All of these potential associations would have been missed if only
European populations were studied.
As might be expected based on the observation that carboplatin
and cisplatin phenotypes were correlated, we observed an
enrichment of carboplatin-associated SNPs in the results of
cisplatin-associated SNPs. Both carboplatin and cisplatin are
platinating agents that act through the formation of intrastrand
and interstrand cross-links on DNA, which result in DNA strand
breaks leading to cell death [30]. The two agents are often used
interchangeably, especially in the treatment of ovarian and lung
cancers [26]. These results support that common genetic
mechanisms may influence the effects of both drugs. In contrast,
a smaller shift in mean p-value was found when comparing the
overall p-value distribution to the cisplatin-SNP p-value distribu-
tion for unrelated drugs cytarabine and 59-DFUR even though
both phenotypes are also correlated with cisplatin, albeit to a lesser
degree (Table 1). Studies in larger cohorts are needed to define
common genetic mechanisms within and among chemotherapeu-
tic classes.
The VEGAS gene-based method revealed two linked genes
associated with both carboplatin- and cisplatin-induced cytotox-
icity in ASW and YRI. One of these genes, COPS5, is also know as
JAB1 (Jun activation domain-binding protein 1) and encodes a
protein involved in multiple signaling pathways [41]. Overexpres-
sion of COPS5 has been implicated in the pathogenesis of several
types of cancer in humans and in some cases has correlated with
poor prognosis [42–46]. In one study, loss of COPS5 expression
sensitized both mouse primary embryonic fibroblasts and
osteosarcoma cells to radiation-induced apoptosis [41]. COPS5 is
linked to three other genes on chromosome 8 that also associated
with cisplatin IC50 in the gene-based analysis (Figure 6). The p-
values of two of these three genes for association with carboplatin
IC50 were just above our suggestive threshold of p#10
23.
Although COPS5 is the only gene of these four known to be
involved in tumorigenesis, the possibility that the others are
involved in susceptibility to platinating agents cannot be ruled out
due to the strong linkage disequilibrium in the region.
Two of the genes that associated with chemotherapeutic-
induced cytotocity in the gene-based analysis in both populations
are candidate tumor suppressors. TP53I11 associated with
cytarabine AUC and overexpression of the gene promotes
apoptosis in hepatocellular carcinoma cells [47]. GAS8, which
associated with cisplatin IC50, is sometimes deleted in breast and
prostate cancer [48,49]. Further studies are needed to elucidate
S1). (B) rs417245, which is 546 kb upstream of F-box only protein 33 (FBXO33), associated with ASW 59-DFUR AUC (p=9.6610
27) and the expression
of two genes in YRI (Table S1). (C) The SNP rs9828664 in the first intron of calcium channel, voltage-dependent, alpha 2/delta subunit 3 (CACNA2D3)
associated with ASW carboplatin IC50 (p=2.5610
26) and the expression of two genes in YRI (Table S1). Plots were made with LocusZoom [67] and the
color of each dot represents the SNP’s linkage disequilibrium r
2 in the YRI with the labeled SNP (purple diamond).
doi:10.1371/journal.pone.0021920.g003
Figure 4. Overall ASW GWAS p-value distributions compared to the p-value distributions of the top cisplatin-associated SNPs. The
p-values for the top 190 cisplatin IC50-associated SNPs (p#10
24) were pulled from the overall list of ,2 million SNPs tested for association with each
drug-induced phenotype (cytarabine AUC, 59-DFUR AUC, carboplatin IC50). The mean p-value in each class is listed across the top. The boxes define
the interquartile range and the thick line is the median. Open dots are possible outliers. The means of the ‘‘All SNPs’’ classes differed from the means
of the ‘‘Top cisplatin SNPs’’ classes for all three drugs (cytarabine p=4.5610
224,5 9-DFUR p=4.4610
224, carboplatin p=2.2610
2191, Student’s t-test).
doi:10.1371/journal.pone.0021920.g004
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based genome-wide analysis may affect tumor cell response to
their associated chemotherapeutic agents.
Our approach to correct for population structure in the
admixed ASW population differs from that taken in other African
American GWA studies [4,50]. Rather than using principal
components to infer global ancestry, we used HAPMIX to infer
local ancestry at each SNP locus and included this value as a
covariate in the association test [38]. Similar local ancestry
approaches were taken in candidate gene studies using Ancestry
Informative Markers [51,52]. Using local ancestry rather than
global ancestry for African Americans more accurately reflects
the structure of the population at each SNP locus and is thus
useful for the single-marker tests of GWA studies. Recently, it was
shown that combining local ancestry and admixture association
signals into a test statistic had more power to map disease loci
than case-control studies correcting for global ancestry only in
African American populations [53]. HAPMIX is one of several
methods for detecting chromosomal segments of distinct ancestry
[54–56] and determining the best way to apply local ancestry in
genetic association tests in admixed populations remains an open
question.
Table 1. Chemotherapuetic-induced cytotoxicity phenotypic Pearson correlations in the ASW.
cytarabine AUC 59-DFUR AUC carboplatin IC50 cisplatin IC50
cytarabine AUC 1 20.11 0.23 0.29
59-DFUR AUC 20.11 1 0.26 0.38
carboplatin IC50 0.23 0.26 1 0.67
cisplatin IC50 0.29 0.38 0.67 1
doi:10.1371/journal.pone.0021920.t001
Figure 5. Gene-based genome-wide association results for chemotherapeutic-induced cytotoxicity in the ASW. Each point represents
a gene. Blue lines are at the suggestive significance threshold of p=10
23. Red lines are at the Bonferroni-adjusted genome-wide significance
threshold of p=2.8610
26 for 17,723 tests.
doi:10.1371/journal.pone.0021920.g005
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limited by SNP genotyping arrays, which were designed to
capture genetic variation in European populations where LD
blocks are larger [3]. Thus, SNP tagging does not work as well in
populations of African ancestry compared to non-African
populations. It is also more difficult to impute genotypes for
African American samples than more genetically homogeneous
populations, although using a pooled reference panel as was done
here with YRI and CEU has been shown to boost performance
[57]. Furthermore, because the LD patterns among variants are
less consistent between African subgroups, it can be more difficult
to replicate associations once they have been detected, unless the
causal variant has been identified [58]. Therefore, we took a
gene-based approach to attempt to replicate our initial ASW
findings in the YRI. We found evidence of replication for 14 of
the 98 genes identified in the ASW using the gene-based GWA
approach, but larger sample sizes are need to confirm these
associations.
Table 2. Genes associated with chemotherapeutic-induced cytotoxicity in the ASW gene-based association studies (p#10
23) that
replicated in the YRI (p,0.05).
Phenotype Chr Gene nSNPs Start Position Stop Position
ASW Test
Statistic ASW p-value
YRI Test
Statistic YRI p-value
cytarabine AUC 11 TP53I11 122 44910474 44929184 309.0 3.3610
24 307.0 1.3610
23
cytarabine AUC 7 CALCR 264 92891734 93041686 706.7 3.3610
24 549.9 3.8610
22
cytarabine AUC 8 STMN4 89 27149730 27171820 272.7 5.2610
24 100.2 4.6610
22
cytarabine AUC 1 KMO 121 239762302 239825567 228.6 5.4610
24 280.5 1.8610
22
carboplatin IC50 21 SNF1LK 108 43658826 43671430 284.4 4.4610
24 388.0 2.8610
22
carboplatin IC50 8 ARFGEF1 63 68272450 68418466 311.9 5.7610
24 200.7 3.0610
22
carboplatin IC50 8 COPS5 18 68117868 68137116 83.5 7.5610
24 81.8 2.3610
22
cisplatin IC50 8 ARFGEF1 63 68272450 68418466 435.4 8.6610
25 192.1 1.7610
22
cisplatin IC50 8 COPS5 18 68117868 68137116 165.7 1.8610
24 63.3 2.0610
22
cisplatin IC50 8 CSPP1 39 68139156 68271050 361.0 2.4610
24 164.0 1.7610
22
cisplatin IC50 8 LRRC67 21 68062920 68103340 143.5 3.1610
24 67.8 2.0610
22
cisplatin IC50 16 PRDM7 47 88650474 88669839 117.2 3.9610
24 105.0 3.3610
22
cisplatin IC50 16 GAS8 58 88616508 88638880 127.8 4.6610
24 118.0 4.1610
22
cisplatin IC50 3 OSTalpha 53 197427779 197444698 120.1 8.7610
24 141.5 1.4610
22
doi:10.1371/journal.pone.0021920.t002
Figure 6. Chromosome 8 cluster of linked genes associated with cisplatin IC50 in ASW and YRI. The four genes associated with cisplatin
IC50 were detected using a gene-based analysis [35]. They are COPS5 (ASW p=1.8610
24, YRI p=0.020), ARFGEF1 (ASW p=8.6610
25, YRI p=0.017),
CSPP1 (ASW p=2.4610
24, YRI p=0.017), and LRRC67 (ASW p=3.1610
24, YRI p=0.020). Plots were made with LocusZoom [67] and the position of
each dot corresponds to the SNP’s p-value for association with carboplatin IC50 in the ASW and the color of each dot represents the SNP’s linkage
disequilibrium r
2 in the YRI with the labeled SNP (purple diamond).
doi:10.1371/journal.pone.0021920.g006
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LD-tagged variation to directly genotyped variation, which will
benefit populations with African ancestry. The ASW population is
in the pipeline to be sequenced by the 1000 Genomes Project
[59,60]. In our gene-based analysis, we only considered SNPs
within a gene region, but trans eQTLs are also known to affect
gene activity [40,61,62]. In future analyses, we plan to extend the
VEGAS method to incorporate additional SNPs discovered by the
1000 Genomes Project and SNPs associated with gene expression
in relevant tissues into the gene-based test. Our results highlight
the importance of studying populations of African descent and we
eventually hope to clinically validate both genes and variants in a
cohort of African American patients treated with one or more of
the chemotherapeutic agents studied to determine their roles in
patient response and toxicity.
Materials and Methods
Lymphoblastoid Cell Lines
International HapMap Project EBV-transformed LCLs from 83
individuals of African ancestry from the Southwestern United
States (ASW [HAPMAPPT07]) and 176 individuals from the
Yoruba in Ibadan, Nigeria (YRI [HAPMAPPT03 and HAP-
MAPPT04] were purchased from the Coriell Institute for Medical
Research. The family structure of the ASW population was 10
trios (mother, father, and child), 20 duos (one parent and child)
and 13 unrelated singletons. The family structure of the YRI was
57 trios, 1 duo and 3 singletons. Cell lines were maintained in
RPMI 1640 (Mediatech, Herndon, VA, USA) supplemented with
15% fetal bovine serum (HyClone Laboratories, Logan, UT, USA)
and 1% L-glutamine (Invitrogen, Carlsbad, CA, USA). Cell lines
were passaged 3 times per week at a concentration of
3.5610
5 cells/mL and incubated at 37uC with 5% CO2 and
95% humidity.
Chemotherapeutic Drugs and Cytotoxicity Assays
Capecitabine is not activated to 5-fluorouracil in LCLs,
therefore 59-deoxyfluoruridine (59-DFUR) (an active form of
capecitabine) was obtained from LKT Laboratories (St. Paul,
MN, USA) and prepared in equal amounts of PBS (Invitrogen,
Carlsbad, CA, USA) and DMSO (Sigma, St. Louis, MO, USA) as
a stock solution at a concentration of 80 mM. Carboplatin [7],
cisplatin [8] and cytarabine [6] were prepared and cells were
treated as previously described. Briefly, the cytotoxic effect of
carboplatin, cisplatin, cytarabine, and 59-DFUR was determined
using a short-term alamarBlue colorimetric assay (Biosource
International, Camarillo, CA). LCLs (.85% viability) were
plated in triplicate at a density of 1610
5 cells/mL and drug
added 24 h after plating. Cells were exposed to cisplatin for 48 h
and the other three drugs for 72 h at the following concentra-
tions: 1, 2.5, 5, 10, and 20 mM cisplatin; 5, 10, 20, 40, and 80 mM
carboplatin; 1, 5, 10, and 40 mM cytarabine; and 2.5, 10, 20, and
40 mM5 9-DFUR. Final percent survival was ascertained by
averaging at least six replicates from two independent experi-
ments. Growth rates for each cell line were estimated by the
alamarBlue method, as previously described [12,63]. The
concentration required to inhibit 50% of cell growth (IC50)w a s
calculated for each carboplatin- and cisplatin-treated cell line.
The area under the survival curve (AUC) was calculated for
cytarabine- and 59-DFUR-treated cell lines using the trapezoidal
rule. All IC50 and AUC values were adjusted for baseline growth
rate and the residuals were rank-transformed to normality before
statistical modeling using the rntransform function in the GenABEL
R library.
Global Ancestry Analysis
We used a linkage disequilibrium-pruned (r
2.0.3) set of
102,386 SNPs to compare the genotypes of unrelated ASW,
YRI (Yoruba from Ibadan, Nigeria), CEU (European descent
from Utah) and CHB (Han Chinese from Beijing) individuals.
Genotypes came from HapMap release 22 for YRI, CEU and
CHB and release 27 for ASW. Principal components were
computed using the EIGENSTRAT method to model the ancestry
of the individuals in these four populations [37].
Local Ancestry Analysis
Local ancestry for each ASW individual at each genotyped SNP
locus was estimated using the HAPMIX software [38]. Phased
genotypes from the HapMap YRI and CEU (release 22)
populations were used as the two parental populations to estimate
the ancestry of the ASW population (release 27). A total of
1,152,289 SNPs that have a minor allele frequency of at least 5%
and are in Hardy-Weinberg equilibrium (p.0.001) in the ASW
were used for further analysis. Suggested input parameters for
African American populations of 20% European ancestry and 6
generations since admixture were used [38]. For each individual,
the algorithm estimated the number of CEU chromosomes
(continuous value between 0 and 2) at each SNP locus.
Genotype Imputation
To increase genome coverage of the ASW, ungenotyped makers
were imputed using the BEAGLE software [64]. Both YRI and
CEU (HapMap r22) were used as reference populations as in Hao
et al. [57]. Beagle imputes ungenotyped markers for unrelateds,
parent-offspring pairs and parent-offspring trios by modeling the
family structure in the analysis. We also used BEAGLE to impute
markers that were not genotyped in YRI phase 3 (r27) by using
YRI phase 2 (r22) as reference. To measure the accuracy of the
imputation at each SNP locus, R
2 was calculated as described
following 100 imputations of the data [64]. Of 1,303,563 SNPs for
which imputation was attempted in the ASW, 1,064,943 (81.7%)
had an imputation R
2.0.80. Imputed SNP genotypes with
R
2.0.80, minor allele frequency.0.05, no Mendelian errors
and in Hardy-Weinberg equilibrium (p.0.001) were carried
through the rest of the analysis. Imputation increased the number
of SNPs tested in the ASW GWAS from 1,152,289 to 2,217,232.
Local ancestry for each imputed SNP was inferred by using the
predicted number of CEU chromosomes from nearest genotyped
SNP.
GWA Analysis
We performed GWA studies in the ASW population between
each rank-transformed drug phenotype adjusted for growth rate
and greater than 2 million SNPs using the quantitative trait
disequilibrium test (QTDT) total association model [65]. Local
ancestry (predicted number of CEU chromosomes at each locus)
was included as a covariate in the model for each drug. Two of the
phenotypes had genomic control lambda (lGC) values [66] greater
than 1 (1.11 for cytarabine AUC and 1.23 for carboplatin IC50).
The lGC is computed as the median of all genome-wide observed
test statistics (chi-square statistics) divided by the expected median
of the test statistic under the null hypothesis of no association
(making the assumption that the number of true associations is
very small compared to the millions of tests performed). The
cytarabine and carboplatin results were corrected for residual
inflation of the test statistic by dividing the observed test statistic at
each SNP by the lGC [66] and then carried through subsequent
analyses. The 59-DFUR and cisplatin GWA results adjusting for
Chemotherapy Pharmacogenomics in African Americans
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respectively) and no correction was used. Q-Q plots of the
corrected models are shown in Figure S1.
We considered chemotherapeutic susceptibility-associated SNPs
with p#10
24 as strongly suggestive and SNPs with p#5610
28 as
genome-wide significant. We chose p#10
24 as suggestive because
previous work has shown that SNPs associated with chemother-
apeutic drug susceptibility at this threshold and below are enriched
for eQTLs, an important functional class [39]. The complete
GWA analysis for 176 YRI cell lines has been performed between
each rank-transformed drug phenotype adjusted for growth rate
and greater than 2 million SNPs using the QTDT [65] total
association model (Amy L. Stark, Heather E. Wheeler, R.
Stephanie Huang, M. Eileen Dolan, unpublished data). We used
the YRI GWA results in the gene-based GWA analysis when
testing the 98 genes found in the ASW for replication in the YRI.
Gene-based GWA Analysis
The versatile gene-based association study (VEGAS) method is
a gene-level analysis that can detect genes associated with a trait
due to multiple SNPs of relatively small effect [35]. We tested the
17,723 genes annotated by the VEGAS software for association
with each of the four drug phenotypes in the ASW population
using the results from the initial SNP-based GWAS. The VEGAS
software combines the contribution of all SNPs in a gene into a
test-statistic and corrects for linkage disequilibrium in each
population by using simulations from the multivariate normal
distribution [35]. In our implementation of VEGAS, the SNP set
for each gene included any SNPs within the gene as well as SNPs
within 50 kb upstream or downstream of the gene. The top 10%
most significant SNPs from the SNP set of each gene were used in
the test-statistic calculation. Similar results were observed when all
the SNPs in the SNP set of each gene were used in the analysis
(Table S2). Up to 10
6 multivariate normal vectors of the
appropriate SNP set size for each gene were simulated, and the
empirical gene-based p-value was calculated as the proportion of
simulated test statistics that exceeded the observed gene-based test
statistic. After completing the ASW VEGAS analysis, we tested the
top 98 genes (p#10
23) for association with the respective
phenotype in the YRI population.
Supporting Information
Figure S1 Q-Q plots of GWA results for chemothera-
peutic-induced cytotoxicity in the ASW. Cytarabine and
carboplatin results were adjusted using the genomic control
method. 59-DFUR and cisplatin results were not adjusted.
(TIF)
Table S1 Top ASW drug-induced cytotoxicity-associated
SNPs (p#10
24).
(XLS)
Table S2 Top ASW drug-induced cytotoxicity-associated
genes (p#10
23).
(XLS)
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